Prospective risk of non-melanoma cancer in CDKN2A melanoma-prone families
| A. CDKN2A mutation-positive and mutation-negative subjects | ||||||||
|---|---|---|---|---|---|---|---|---|
| Tumour type | Obs | Exp | Obs/Exp | (95% CI) | Obs | Exp | Obs/Exp | (95% CI) |
| Mutation-positive subjects (1500 person-years) | Mutation-negative subjects (2138 person-years) | |||||||
| All cancers | 12 | 5.5 | 2.2 | (1.1 to 3.8) | 2 | 6.2 | 0.3 | (0.0 to 1.2) |
| Digestive system | 6 | 0.9 | 6.7 | (2.4 to 14.6) | 0 | |||
| Pancreas | 4 | 0.1 | 38 | (10 to 97) | 0 | |||
| Respiratory system | 1 | 0.8 | 1.2 | (0.0 to 6.5) | 0 | |||
| Breast | 2 | 0.9 | 2.2 | (0.2 to 8.1) | 1 | 1.2 | 0.9 | (0.0 to 4.8) |
| Prostate | 1 | 0.8 | 1.3 | (0.0 to 7.4) | 0 | |||
| Urinary tract | 1 | 0.4 | 2.6 | (0.0 to 14.6) | 0 | |||
| Brain and CNS | 1 | 0.1 | 10.6 | (0.1 to 59.1) | 0 | |||
| Lymphatic and haematopoietic | 0 | 1 | 0.6 | 1.8 | (0.0 to 9.8) | |||
| B. CDKN2A mutation-positive subjects only | ||||||||
|---|---|---|---|---|---|---|---|---|
| Tumour type | Obs | Exp | Obs/Exp | (95% CI) | Obs | Exp | Obs/Exp | (95% CI) |
| Subjects with melanoma (811 person-years) | Subjects without melanoma (689 person-years) | |||||||
| CI, confidence interval; Exp, expected; Obs, observed. | ||||||||
| All cancers | 9 | 3.9 | 2.3 | (1.1 to 4.4) | 3 | 1.6 | 1.9 | (0.4–5.5) |
| Digestive system | 6 | 0.7 | 9.1 | (3.3 to 19.8) | 0 | |||
| Pancreas | 4 | 0.1 | 52 | (13 to 132) | 0 | |||
| Respiratory system | 1 | 0.7 | 1.5 | (0.0 to 8.5) | 0 | |||
| Breast | 0 | 0.5 | (0.0 to 6.9) | 2 | 0.4 | 5.5 | (0.6–20.0) | |
| Prostate | 1 | 0.6 | 1.6 | (0.0 to 8.8) | 0 | |||
| Urinary tract | 1 | 0.3 | 3.4 | (0.0 to 19.0) | 0 | |||
| Brain and CNS | 0 | 0.1 | (0.0 to 58.4) | 1 | 0.03 | 31.9 | (0.4–177.3) | |